Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Reexamination Certificate
2007-10-25
2008-12-02
Martinell, James (Department: 1634)
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
C435S007100, C435S320100, C435S325000
Reexamination Certificate
active
07459300
ABSTRACT:
The present invention relates to a novel human protein called phosphatonin, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
REFERENCES:
patent: 5015628 (1991-05-01), Reynolds
patent: 5407644 (1995-04-01), Rytter et al.
patent: 5837674 (1998-11-01), Kumagai et al.
patent: 5849865 (1998-12-01), Cheng et al.
patent: 6027592 (2000-02-01), Tseng et al.
patent: 6045780 (2000-04-01), Bixler et al.
patent: 6145655 (2000-11-01), Tsai
patent: 6300062 (2001-10-01), Cerny et al.
patent: 6329357 (2001-12-01), Norman et al.
patent: 6673900 (2004-01-01), Rowe
patent: 6790639 (2004-09-01), Brown et al.
patent: 6818745 (2004-11-01), Rowe
patent: 6911425 (2005-06-01), Kumagai et al.
patent: 7098185 (2006-08-01), Rowe
patent: 2002/0102641 (2002-08-01), Schia Vi et al.
patent: 2002/0197267 (2002-12-01), Kumagai et al.
patent: 2003/0166239 (2003-09-01), Brown et al.
patent: WO 95/14714 (1995-06-01), None
patent: WO 99/08730 (1999-02-01), None
patent: WO 99/43844 (1999-09-01), None
patent: WO 99/48909 (1999-09-01), None
patent: WO 99/60017 (1999-11-01), None
patent: WO 00/52041 (2000-09-01), None
patent: WO 01/72826 (2001-10-01), None
patent: WO 02/05836 (2002-01-01), None
Abe et al., “Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamine D3”PNAS, 78(8):4990-4994 (1981).
Bairoch et al., “EF-hand motifs in inositol phospholipid-specific phospholipase C”FEBS, 269(2:454-456 (1990).
Bikle, “Vitamin D: New Actions, New Analogs, New Therapeutic Potential; Update 1995”Endocrine Review, 4(1):77-83 (1995).
Brenza et al., “Parathyroid hormone activation of the 25-hydroxyvitamine D3-1α-Hydroxylase gene promoter”PNAS95:1387-1391 (1998).
Carpenter (1997) “New Perspectives on the Biology and Treatment of X-linked Hypophosphatemic Rickets,” Pediatric Endocrinology, vol. 44(2):443-466.
Carswell, “The Potential for Treating Neurodegenerative Disorders with NGF-Inducing Compounds”Experimental Neurology, 124:36-42 (1993).
Chappard et al. , “Effects of Tiludronate on Bone Loss in Paraplegic Patients”Journal of Bone Mineral Research, 10(1):112-118 (1995).
Chauvaux et al., “Calcium-binding affinity and calcium-enhanced activity ofClostridium thermocellumendoglucanase D”Biochem J., 265:261-265 (1990).
Davis, “The Many Faces of Epidermal Growth Factor Repeats”The New Biologist, 2(5):410-419 (1990).
Economou et al., “The Rhizoblum nodulation gene nodO encodes a CA2+-binding protein that is exported without N-terminal cleavage and is homologous to haemolysin and related proteins”The EMBO Journal, 9(2):349-354 (1990).
Ecarot et al. (1992) “Defective Bone Formation by Hyp Mouse Bone Cells Transplanted into Normal Mice: Evidence in Favor of an Intrinsic Osteoblast Defect.”Journal of Bone and Mineral Research, vol. 7(2):215-220.
Ecarot et al. (1995) “Effect of 1,25-Dihydroxyvitamin D3 Treatment on Bone Formation by Transplanted Cells from Normal and X-Linked Hypophosphatemic Mice.” Journal of Bone and Mineral Research, vol. 10(3):424-431.
Eto et al., “Assay of 25-Hydroxyvitamin D3 1 α-Hydroxylase in Rat Kidney Mitochondria”Analytical Biochemistry, 258:53-58 (1998).
Ferris et al., “RGD-coated titanium implants stimulate increased bone formation in vivo”Biomaterials, 20:2323-2331 (1999).
Fisher et al., “Inhibition of Osteoclastic Bone Resorption in Vivo by Eschistatin an “Arginyol-Glycyl-Aspartyl” (RGD)-Containing Protein”Endocrinology, 132(3):1411-1413 (1993).
Fratzl et al., “Abnormal Bone Mineralization After Fluoride Treatment in Osteoporosis: A Small-Angle X-ray Scattering Study”Journal of Bone and Mineral Research9(10):1541-1549 (1994).
Gennari et al., “Management of Osteoporosis and Paget's Disease”Drug Safety, 11(3):179-195 (1994).
George et al., “Characterization of a Novel Dentin Matrix Acidic Phosphoprotein”The Journal of Biological Chemistry, 268(17):12624-12530 (1993).
Gronowicz et al., “Synthetic Peptide Containing Arg-Gly-Asp Inhibits Bone Formation and Resportion in a Mineralizing Organ Culture System of Fetal Rat Parietal Bones”Journal of Bone and Mineral Research9:193-201 (1994).
Hayashibara et al., “A Synthetic Peptide Fragment of Human MEPE Stimulates New Bone Formation In Vitro and In Vivo”Journal of Bone and Mineral Research19(3):1-8 (2004).
Hewison et al., “1α-Hydroxylase and the action of vitamin D”Journal of Molecular Endocrinology, 25:141-148 (2000).
Hilfiker et al., “Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine”PNAS, 95:14564-14569 (1998).
Horton et al., “Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23C6 Inhibit Dentine Resorption and Cell Spreading by Osteoclasts”Experimental Cell Research, 195:368-375 (1991).
Inomata et al., “Effect of 1α(OH)-vitamin D3 on insulin secretion in diabetes mellitus”Bone and Mineral, 1:187-192 (1986).
Kato et al., “Molecular Genetics of Vitamin D-Dependent Hereditary Rickets”Hormone Research, 57:73-78 (2002).
Kawasaki et al., “Calcium-Binding Proteins 1: EF Hands”Protein Profile, 2(4):305-356 (1995).
Kimmel-Jehan et al., “Cloning of the mouse 25-hydroxyvitamin D3-1α-hydroxylase (CYP1α) gene”Biochimica et Biophysica Acta, 1475:109-113 (2000).
Lajeunesse et al. (1996) “Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse.” Kidney International, vol. 50:1531-1538.
Lopez-Moratalla et al., “A common structural motif in immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and Th1 cells”Biochimica et Biophysica Acta, 1317:183-191 (1996).
Lufkin et al., “Pamidronate: An Unrecognized Problem in Gastrointestinal Tolerability”Osteoporosis Int.4:320-322 (1994).
Martin et al., “Strategies to Minimize Bone Disease in Renal Failure”American Journal of Kidney Diseases, 38(6):1430-1436 (2001).
Meyer et al. (1989) “The Renal Phosphate Transport Defect in Normal Mice Parabiosed to X-linked Hypophosphatemic Mice Persists After Parathyroidectomy.” Journal of Bone and Mineral Research, vol. 4(4):523-532.
Meyer et al. (1989) “Parabiosis Suggests a Humoral Factor is Involved in X-Linked Hypophosphatemia in Mice.” Journal of Bone and Mineral Research, vol. 4(4):493-500.
Miller et al., “Genetics of vitamin D biosynthesis and its disorders”Best Practice&Research Clinical Endocrinology and Metabolism, 15(1):95-109 (2001).
Moncrief et al., “Evolution of EF-Hand Calcium-Modulated Proteins. I. Relationships Based on Amino Acid Sequences”J. Mol Evol., 30:522-562 (1990).
Morgan et al. (1974) “Renal Transplantation in Hypophosphatemia with Vitamin D-Resistant Rickets.” Arch Intern Med., vol. 134:549-552.
Muller et al., “1α,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro”Immunology Letters, 17:361-366 (1988).
Mundy et al., “Stimulation of Bone Formation in Vitro and in Rodents by Statins”Science, 286:1946-1949 (1999).
Nesbitt et al., “Abnormal Parathyroid Hormone-Realted Peptide Formulation of Renal 25-Hydroxyvitamin D-1-Hydroxylase In Hyp Mice: Evidence for a Generalized Defect of Enzyme Activity in the Proximal Convoluted Tubule”Endocrinology, 127(2):843-848 (1990).
Nesbitt et al. (1992) “Crosstransplantation of Kidneys in Normal and Hyp Mice.&
Bozicevic Karl
Bozicevic Field & Francis LLP
Martinell James
University College London
LandOfFree
Polypeptide Hormone Phosphatonin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide Hormone Phosphatonin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide Hormone Phosphatonin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021141